{"id":"docetaxel-nedaplatin-and-capecitabine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Stomatitis"},{"rate":"5-20%","effect":"Hand-foot syndrome"},{"rate":"5-20%","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. Nedaplatin forms platinum-DNA adducts, which interfere with DNA replication and transcription. Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis.","oneSentence":"Docetaxel is a microtubule inhibitor that disrupts cell division, nedaplatin is a platinum-based DNA crosslinker, and capecitabine is a thymidylate synthase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:59.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT03503136","phase":"PHASE3","title":"Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06","conditions":"Nasopharyngeal Carcinoma","enrollment":632}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TNX induction chemotherapy"],"phase":"phase_3","status":"active","brandName":"docetaxel, nedaplatin, and capecitabine","genericName":"docetaxel, nedaplatin, and capecitabine","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel is a microtubule inhibitor that disrupts cell division, nedaplatin is a platinum-based DNA crosslinker, and capecitabine is a thymidylate synthase inhibitor. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}